

# ACORDA THERAPEUTICS INC

Reported by  
**COHEN RON**

## FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 11/03/06 for the Period Ending 11/01/06

Address	420 SAW MILL RIVER ROAD ARDSLEY, NY 10502
Telephone	914-347-4300
CIK	0001008848
Symbol	ACOR
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31



**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	(1)		S		700	D	\$17.25	383061	D	
Common Stock	11/1/2006 (1)		S		218	D	\$17.24	382843	D	
Common Stock	11/1/2006 (1)		S		1000	D	\$17.22	381843	D	
Common Stock	11/1/2006 (1)		S		1151	D	\$17.21	380692	D	
Common Stock	11/1/2006 (1)		S		1449	D	\$17.20	379243	D	
Common Stock	11/1/2006 (1)		S		900	D	\$17.19	378343	D	
Common Stock	11/1/2006 (1)		S		1200	D	\$17.18	377143	D	
Common Stock	11/1/2006 (1)		S		4400	D	\$17.16	372743	D	
Common Stock	11/1/2006 (1)		S		2450	D	\$17.15	370293	D	
Common Stock	11/1/2006 (1)		S		400	D	\$17.14	369893	D	
Common Stock	11/1/2006 (1)		S		1200	D	\$17.13	368693	D	
Common Stock	11/1/2006 (1)		S		1135	D	\$17.12	367558	D	
Common Stock	11/1/2006 (1)		S		3192	D	\$17.11	364366	D	
Common Stock	11/1/2006 (1)		S		1815	D	\$17.10	362551	D	
Common Stock	11/1/2006 (1)		S		1200	D	\$17.07	361351	D	
Common Stock	11/1/2006 (1)		S		1038	D	\$17.05	360313	D	
Common Stock	11/1/2006 (1)		S		200	D	\$17.03	360113	D	

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				

**Explanation of Responses:**

(1) Sale pursuant to a 10b5-1 plan

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
COHEN RON C/O ACORDA THERAPEUTICS, INC.	X		President & CEO	

15 SKYLINE DRIVE  
HAWTHORN, NY 10532

**Signatures**

**Ron Cohen by Jane Wasman, Attorney-in-Fact**

**11/3/2006**

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.